The New AI Adoption Question in Medicine Is Not Capability — It’s Trust
MedCity News argues that trust, not raw model performance, is becoming the bottleneck for AI adoption in medicine. As vendors push deeper into clinical workflows, health systems are asking whether the tools are transparent, auditable, and reliable enough to use at scale.
AI in medicine has moved past the novelty phase. The current debate is no longer whether these systems can do something useful, but whether clinicians, administrators, and patients believe they should be allowed to do it routinely.
That is the core message in MedCity News’s look at trust and AI adoption. The article reflects a broader industry shift: health care buyers are increasingly skeptical of impressive demos and more focused on operational evidence—how the model performs on their patients, how often it fails, who owns the liability, and whether the workflow actually improves.
This matters because trust in health care is cumulative. A system that is accurate most of the time but opaque when it errs can still be a poor fit for clinical practice. The organizations that win in this market will likely be the ones that can document performance, explain limitations, and support human oversight rather than trying to replace it.
In practice, that means AI adoption is becoming less about model size and more about governance. The vendors that can make clinicians comfortable will be the ones that can show safety, accountability, and measurable value—not just technical ambition.